Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Prevención de la transmisión vertical y tratamiento de la infección por el vi...
Información de la revista
Vol. 19. Núm. 7.
Páginas 314-335 (Agosto 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 7.
Páginas 314-335 (Agosto 2001)
DOI: 10.1016/S0213-005X(01)72652-3
Acceso a texto completo
Prevención de la transmisión vertical y tratamiento de la infección por el virus de la inmunodeficiencia humana en la mujer embarazada
Visitas
...
José A. Iribarrena,c, José T. Ramosb, Luis Guerrac, Oriol Colld, María Isabel de Joséb,c, Pere Domingoa, Claudia Fortunyb, Pilar Mirallesa, Francisco Parrasc, José María Peñaa, Carlos Rodrigoa, Ricard Vidald
a GESIDA-SEIMC
b Asociación Española de Pediatría
c Consejo Asesor Clínico del Plan Nacional sobre el Sida
d Sociedad Española de Ginecología y Obstetricia
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
TheWorking Group of Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV in Africa, America and Europe: results from 13 perinatal studies.
J Acquir Immune Def Syndr, 8 (1995), pp. 506-510
[2.]
UNAIDS/WHO Working Group on Global HIV/AIDS and STD Surveillance. Report on the Global HIV/AIDS Epidemic. Estimación en Diciembre 1999 Ginebra: World Health Organization;1999. Disponible en.http//www.Unaids.Org/unaids/document/epidemio/report99.html
[3.]
Centro Nacional de Epidemiología. Vigilancia del SIDA en España. Informe trimestral Nº 3, 1999
[4.]
J.T. Ramos, J. Ruiz-Contreras, R. Bastero, C. Barrio, P. Moreno, R. Delgado, et al.
Estimación de de la prevalencia de infección VIH en la embarazada, efectividad de la ZDV en la prevención de la transmisión vertical.
Med Clin (Barc, 114 (2000), pp. 245-252
[5.]
Informe de la Secretaría del Plan Nacional sobre el sida y las CC.AA. de Baleares, Canarias, Castilla La Mancha, Castilla y León, Galicia, Melilla y Murcia. Estudio anónimo y no relacionado sobre la prevalencia de anticuerpos anti-VIH 1-2 en recién nacidos de 7 Comunidades Autónomas. Años 1996-1999.
[6.]
Secretaría del Plan Nacional sobre el sida, Registros autonómicos de casos de sida, Centro Nacional de Epidemiología. Vigilancia epidemiológica del sida en España. Registro Nacional. Informe Semestral nº1, año 2000. Disponible en http/www.msc/es/sida/epidemiologia/actualizada/2000-01.pdf
[7.]
Muñoz L, Bernal A, Noguer I, García Sainz A. Evolución de la infección del VIH-1 por transmisión vertical en España (1993-1999). IX Congreso de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Santiago de Compostela, 21-24 de mayo de 2000. Abstract 407.
[8.]
J. Echeverria Lecuona, J.J. Landa Maya, J.A. Iribarren Loyarte.
Evolution of the strategies in the attention to gestant woman HIV (+) and its influence in vertical transmission.
pp. 107
[9.]
M.L. Newell.
Mechanisms and timing of mother-to-child transmission.
AIDS, 12 (1998), pp. 831-837
[10.]
S.H. Landesman, L.A. Kalish, D.N. Burns, H. Minkoff, H.E. Fox, C. Zorrilla, et al.
Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child.
N Engl J Med, 334 (1996), pp. 1617-1623
[11.]
M.J. Mayaux, M. Burgard, J.P. Teglas, J. Cottalorda, A. Krivine, F. Simon, et al.
Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease.
JAMA, 275 (1996), pp. 606-610
[12.]
M.J. Mayaux, E. Dussaix, J. Isopet, C. Rekacewicz, L. Mandelbrot, N.C. Vigneron, et al.
Maternal virus load during pregnancy and mother to child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies.
J Infect Dis, 175 (1997), pp. 172-175
[13.]
L. Mandelbrot, J. Le Chenadec, A. Berrebi, A. Bongain, J.L. Benifla, J.F. Delfraissy, et al.
Perinatal HIV transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort.
JAMA, 280 (1998), pp. 55-60
[14.]
L.M. Mofenson, C.M. Wilfert.
Pathogenesis and interruption of vertical transmission.
Pediatric AIDS. The challenge of HIV infection in infants, children and adolescents, pp. 487-513
[15.]
L. Kuhn, D.M. Thea, R.W. Steketee.
for the perinatal AIDS colaborative group.
Preterm delivery and risks of intrauterine and intrapartum HIV transmission, pp. 243
[16.]
The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies.
AIDS, 15 (2001), pp. 357-368
[17.]
V. Leroy, M.L. Newell, F. Dabis, C. Peckham, P. Van de Perre, M. Bulterys, et al.
International multicentre pooled analysis of late postnatal motherto-child transmission of HIV-1 infection.
Lancet, 352 (1998), pp. 597-600
[18.]
A. Coutsoudis, K. Pillay, E. Spooner, L. Kuhn, H.M. Coovadia.
Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 infection.
Lancet, 354 (1999), pp. 471-476
[19.]
R.W. Nduati, G.C. John, D. Mbori-Ngacha, B. Richardson, J. Overbaugh, A. Mwatha, et al.
Effect of breastfeeding and formula feeding on transmission of HIV-1:a randomized clinical trial.
JAMA, 283 (2000), pp. 1167-1174
[20.]
The European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one.
AIDS, 13 (1999), pp. 1377-1385
[21.]
W. Borkowsky, K. Krasinki, Y. Cao, D. Ho, H. Pollack, T. Moore, et al.
Correlation of perinatal transmission of human immonodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes.
J Pediatr, 125 (1994), pp. 345-351
[22.]
G. Fang, H. Burger, R. Grimson, P. Tropper, S. Nachman, D. Mayers, et al.
Maternal plasma human immonodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.
Proc Natl Acad Sci USA, 92 (1995), pp. 12100-12104
[23.]
R.E. Dickover, E.M. Garratty, S.A. Herman, M.S. Sim, S. Plaeger, P.J. Boyer, et al.
Identification of levels of maternal HIV-1 RNA associated wirh risk of perinatal transmission: effect of maternal zidovudine treatment on viral load.
JAMA, 275 (1996), pp. 599-605
[24.]
L.M. Mofenson, J.S. Lambert, E.R. Stiehm, J. Bethel, W.A. Meyer III, J. Whitehouse, et al.
Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine.
N Engl J Med, 341 (1999), pp. 385-393
[25.]
P.M. García, L.A. Kalish, J. Pitt, H. Minkoff, T.C Quinn, S.K Burchett, et al.
Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission.
N Engl J Med, 341 (1999), pp. 394-402
[26.]
W. Blattner, E. Cooper, M. Charurat, B. Thompson, C. Hanson, L. Mofenson, et al.
Effectiveness of potent anti-retroviral therapies on reducing perinatal transmission of HIV-1.
Programme Supplement, pp. 4
[27.]
P.A. Mock, N. Shaffer, C. Bhadrakom, W. Siriwasin, T. Chotpitayasunondh, S. Chearskul, et al.
Maternal viral load and timing of mother-to-child transmission, Bangkok, Thailand.
AIDS, 13 (1999), pp. 407-414
[28.]
N. Shaffer, A. Roongpisuthipong, W. Siriwasin, T. Chotpitayasunondh, S. Chearskul, N.L. Young, et al.
Maternal virus load and perinatal human immunodeficiency virus type 1 subtipe E transmission, Thailand.
J Infect Dis, 179 (1999), pp. 590-599
[29.]
D.G. Contopoulos-Ioannidis, J.P. Ioannidis.
Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: a meta-analysis.
J Acquir Immune Defic Syndr Hum Retrovirol, 18 (1998), pp. 126-135
[30.]
J.P.A Ioannidis, E.J. Abrams, A. Ammann, M. Bulterys, J.J. Goedert, L. Gray, et al.
Perinatal transmission of Human Immunodeficiency Virus Type 1 by pregnant women with RNA visus loads <1000 copies/ml.
J Infect Dis, 183 (2001), pp. 539-545
[31.]
A.M. Cu-Uvin, A.M. Caliendo, S. Reinert, A. Chang, C. Juliano-Remollino, T.P. Flanigan, et al.
Effect of highly active antiretroviral therapy on cervicovaginal HIV-RNA.
AIDS, 14 (2000), pp. 415-422
[32.]
F. Shaheen, A.V. Sison, L. McIntosh, M. Mukhtar, R.J. Pomerantz.
Analysis of HIV-1 in the cervicovaginal secretions and blood in pregnant ant nonpregnant women.
J Hum Virol, 2 (1999), pp. 154-166
[33.]
C.E. Hart, J.L. Lennox, M. Pratt-Palmore, T.C. Wright, R.F. Schinazi, T. Evans-Strickfaden, et al.
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract.
Infect Dis, 179 (1999), pp. 871-882
[34.]
A.K. Iversen, A.R. Larsen, T. Jensen, L. Fugger, U. Balslev, S. Wahl, et al.
Distinct determinants of human immunodeficiency virus type 1 RNA and DNA loads in vaginal and cervical secretions.
J Infect Dis, 177 (1998), pp. 1214-1220
[35.]
M.F. Rogers, N. Shaffer.
Reducing the risk of maternal transmission of HIV by attacking the virus.
N Engl J Med, 341 (1999), pp. 441-442
[36.]
L.M. Mofenson, J.A. McIntyre.
Advances and research directions in the prevention of mother-to-child HIV-1 transmission.
Lancet, 355 (2000), pp. 2.237-2.241
[37.]
A. Coutsoudis, K. Pillay, E. Spooner, L. Kuhn, H.M. Coovadia.
Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa.
AIDS, 13 (1999), pp. 1517-1524
[38.]
E.R. Stiehm, J.S. Lambert, L.M. Mofenson, J. Bethel, J. Whitehouse, R. Nugent, et al.
Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
J Infect Dis, 179 (1999), pp. 567-575
[39.]
R.J. Biggar, P.G. Miotti, T.E. Taha, L. Mtimavalye, R. Broadhead, A. Justesen, et al.
Perinaral intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission.
Lancet, 347 (1996), pp. 1647-1650
[40.]
P. Msellati, N. Meda, V. Leroy, R. Likikouet, P. van de Perre, M. Cartoux, et al.
Safety and acceptability of vaginal disinfection with benzalkonium chloride in HIV infected pregnant women in west Africa: ANRS 049b phse II randomized, double blinded placebo controlled trial. DITRAME Study Group.
Sex Transm Infect, 75 (1999), pp. 420-425
[41.]
E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, M.J. O’Sullivan, et al.
Reduction of maternal-infant transmission of human immunodeficiency virus type with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
N Engl J Med, 331 (1994), pp. 1173-1180
[42.]
N. Shaffer, R. Chuachoowong, P.A. Mock, C. Bhadrakom, W. Siriwasin, N.L. Young, et al.
Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group.
Lancet, 353 (1999), pp. 773-780
[43.]
S.Z. Wiktor, E. Ekpini, J.M. Karon, J. Nkengasong, C. Maurice, S.T. Severin, et al.
Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d´ Ivoire: a randomised trial.
[44.]
F. Dabis, P. Msellati, N. Meda, C. Welffens-Ekra, B. You, O. Manigart, et al.
6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HV in breastfed children in Côte d´Ivoire and Burkina Faso: a double-blind placebo controlled multicentre trial. DITRAME (Diminution de la Transmission Mere-Enfant) Study Group.
Lancet, 353 (1999), pp. 786-792
[45.]
L.A. Guay, P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, et al.
Intrapartum and neonatal single-dosis nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
[46.]
J. Echeverria Lecuona, J.J. Landa Maya, J.A. Iribarren Loyarte.
Saba J on behalf of PETRA Trial Study Team.
Interim Analysis of early efficacy of three short ZDV/LMV combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA Trial, pp. 7
[47.]
M.L Lindegren, B. Byers, M. Roger, P. Wortley, P. Gleming.
On the verge of elimination of perinatal acquired HIV/AIDS.
Updated trends in HIV/AIDS in US, pp. 228
[48.]
R.S. Sperling, D.E. Shapiro, R.W. Coombs, J.A. Todd, S.A. Herman, G.D. McSherry, et al.
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant.
N Engl J Med, 335 (1996), pp. 1621-1629
[49.]
Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood- France, United Kingdom, and United States, January 1988-August 1994.
MMWR Morb Mortal Wkly Rep, 44 (1995), pp. 929-933
[50.]
DITRAME ANRS049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children.
Lancet, 354 (1999), pp. 11
[51.]
J.B. Jackson, M. Mracna, L. Guay, J.A. Dileanis, P. Musoke, F. Mmiro, et al.
Selection of nevirapine (NVP) reistance mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET 012).
Programme Supplement, pp. 13
[52.]
N.A. Wade, G.S. Birkhead, B.L. Warren, T.T. Charbonneau, P.T. French, L. Wang, et al.
Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus.
N Engl J Med, 339 (1998), pp. 1409-1414
[53.]
S. Blanche, C. Rouzioux, L. Mandelbrot, J.F. Delfraissy, M.J. Mayaux.
Zidovudine-lamivudine for prevention of mother to child transmission.
DermatologÍa clÍnica, pp. 267
[54.]
S.Z. Wiktor, V. Leroy, E.R. Ekpini, A. Alioum, J. Karon, P. Msellati, et al.
24-month efficacy of short-course maternal zidovudine for the prevention of mother-to-child transmission in a breast feeding population: A poled analysis of two randomized clinical trials in West Africa.
Programme and Abstracts, pp. 354
[55.]
G. Gray, P.O. Bertsahm.
The Petra Study: early and late efficacy of three short ZDV/LMV combination regimens to prevent mother-to-child transmission of HIV-1.
Programme Supplement, pp. 5
[56.]
R. Nduati, B. Richardson, G. John, D. Mbori-Ngacha, J. Overbaugh, T. Mwatha, et al.
Impact of breatfeeding on maternal mortality among HIV-infected women: results of a randomized clinical trial.
Programme and Abstracts, pp. 495
[57.]
G. Gray, J. McIntyre, B. Jivkov, M. Schorn, S. Lala, L. Reynolds, et al.
Preliminary efficacy, safety, tolerability and pharmacokinetics of short course regimens of nucleoside analogues for the prevention of mother-tochild transmission (MCTC) of HIV.
Programme and Abstracts, pp. 355
[58.]
D. Moodley.
The SAINT Trial: Nevirapine (NVP) versus zidovudine (ZDV)+lamivudine (LMV) in prevention of peripartum HIV transmission.
Programme Supplement, pp. 2
[59.]
Dorenbaum A for The PPACTG 316 Study Team.
Report of results of PPACTG 316: An International phase III trial of standars antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission, pp. 7
[60.]
P. Lorenzi, V.M. Spicher, B. Laubereau, B. Hirschel, C. Kind, C. Rudin, et al.
Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects.
AIDS, 12 (1998), pp. F241-F247
[61.]
M.J. OSullivan, G. Scott, S. Yasin, C. Mitchell, W. Scott, M. Duthely.
Protease inhibitors: Is preterm delivery a risk?.
Am J Obstet Gynecol, (1999; 180(1S-II):105S),
[62.]
A. Morris, C. Zorrilla, M. Vajaranant, A. Dobles, S. Cu-uvin, T. Jones, et al.
A review of protease inhibitors use in 89 pregnancies.
pp. 686
[63.]
A. Stek, M. Khoury, F. Kramer, J. Homans, C. Rother, A. Kovacs.
Maternal and Infant Outcomes with Highly Active Antiretroviral Therapy During Pregnancy.
pp. 687
[64.]
D. Shapiro, R. Tuomala, R. Samelson, S. Burchett, G. Ciupak, J. McNamara, et al.
Antepartum antiretroviral Therapy ans Pregnancy.
Outcomes in 462 HIV-Infected Women in 1998-1999 (PPACTG 367), pp. 664
[65.]
Frenkel LM. Pediatric Potpourri. 7th Conference on Retrovirus and Opportunistic Infections. San Francisco. Summary 4 February 2000 Disponible en http//www.medscape.com
[66.]
S. Limpongsanurak, R. Van Leeuwen, C. Macleod.
for the Ritonavir Vertical Transmission Study Group.
Safety, tolerability and efficacy of ritonavir in the prevention of vertical transmission, pp. 241
[67.]
Y. Bryson, A. Stek, M. Mirichnick, J. Connor, S. Huang, M. Hughes, et al.
PPACTG 353.
A Phase I Study of Safety, Pharmacokinetics, and Antiviral Activity of Combination Nelfinavir (NFV), ZDV and LMV in HIV-Infected Pregnant Women and Their Infants, pp. 715
[68.]
S. Edwards, N. Larbalestier, P. Hay, A. de Ruiter, J. Welch, G. Tatlor, P. Easterbrook.
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
pp. 757
[69.]
R.S. Sperling, D.E. Shapiro, G.D. McSherry, P. Britto, B.E. Cunningham, M. Culnane, et al.
Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study.
AIDS, 12 (1998), pp. 1805-1813
[70.]
M. Culnane, M.G. Fowler, S.S. Lee, G. McSherry, M. Brady, K. ODonnell, et al.
Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women.
JAMA, 281 (1999), pp. 151-157
[71.]
I.C. Hanson, T.A. Antonelli, R.S. Sperling, J.M. Oleske, E. Cooper, M. Culnane, et al.
Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine.
J Acquir Immune Def Syndr, 20 (1999), pp. 463-467
[72.]
S. Blanche, M. Tardieu, P. Rustin, A. Slama, B. Barrte, G. Firtion, et al.
Persistent mitochondrial dysfunction and perinatal exposure to antirtroviral nucleoside analogues.
Lancet, 354 (1999), pp. 1084-1089
[73.]
C. Hanson, M. Frederick, M. McIntosh.
Evaluation of Living Uninfected Children for Mitochondrial Defects: Women and Infants Transmission Study.
pp. 665
[74.]
G. Birkhead, N. Wadw, A. Storfer-Isser, B. Gallagher, T. Singh, K. Bornschlegel.
Review of Deaths among a Cohort of New York State (NYS) Infants Exposed in the Perinatal Period to HIV and Antiretroviral Drugs.
pp. 692
[75.]
K. McIntosh.
Mitochondrial Toxicity of Perinatally Administered Zidovudine.
pp. 14
[76.]
The European Collaborative Study and the Swiss Mother+Child HIV Cohort. Combination antiretroviral therapy and duration of pregnancy.
AIDS, 14 (2000), pp. 2913-2920
[77.]
R. Martin, P. Boyer, H. Hammill, H. Peavy, A. Platzker, R. Settlage, et al.
Incidence of premature birth and neonatal respiratory disease in infants of HIV-positive mothers.
J Pediatr, 131 (1997), pp. 851-856
[78.]
J.S. Lambert, D.H. Watts, L. Mofenson, R.E.R. Stiem, R. Harris, J. Bethel, et al.
Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine.
AIDS, 14 (2000), pp. 1389-1399
[79.]
P.M. García, D.H. Watts, H.E. Fox, R. Samelson, E. Rodríguez, C. Schwamlein, et al.
Assesing the Teratogenic Potential of Antiretroviral Drugs: Data from the Antiretroviral Pregnancy Registry.
pp. 68
[80.]
Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States May, 4. 2001. Disponible en el apartado «Recomendaciones» en la dirección: www.gesidaseimc.com
[80.]
D.E. Boxwell, B.A. Styrt.
Lactic acidosis in patients receiving nucleoside reverse trancriptase inhibitors.
pp. 1284
[82.]
J.A. Ibdah, Z. Yang, M.J. Bennett.
Minireview: Liver disease in pregnancy and fetal fatty acid oxidation defects.
Molecular Genetics and Metabolism, 71 (2000), pp. 182-189
[83.]
A. Carr.
State-of-the-Art Summary and Discussion: Issues in metabolic complications: Controversy or Consensus.
pp. 64
[84.]
I.S. Fortgang, P.C. Belitsos, R.E. Chaisson, R.D. Moore.
Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy.
Am J Gastroenterol, 90 (1995), pp. 1433-1436
[85.]
Y. Gerard, L. Maulin, Y. Yazdanpanah, X. De La Tribonniere, C. Amiel, C.A. Maurage, et al.
Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy.
AIDS, 14 (2000), pp. 2723-2730
[86.]
R. Luzzati, P. Del Bravo, G. Di Perri, A. Luzzani, E. Concia.
Riboflavine and severe lactic acidosis.
[87.]
Bristol-Myers Squibb Company. Healthcare Provider Important Drug Warning Letter. January 5 2001.
[88.]
C.J. Foster.
Evolution of the strategies in the attention to gestant woman HIV (+) and its influence in vertical transmission.
[89.]
M.S. Hirsch, F. Brun-Vézinet, R.T. D´Aquila, S.M. Hammer, V. Johnson, D.R. Kuritzkes, et al.
Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection. Recommendations of an International AIDS Society-USA Panel.
JAMA, 283 (2000), pp. 2417-2426
[90.]
C.A. Siegrist, S. Yerly, L. Kaiser, C.A. Wyler, L. Perrin.
Mother to child transmission of zidovudine-resistant HIV-1.
Lancet, 344 (1994), pp. 1771-1772
[91.]
L.M. Frenkel, L.E. Wagner, L.M. Demeter, S. Dewhurst, R.W. Coombs, B.L. Murante, R.C. Reichman.
Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1.
Clin Infect Dis, 20 (1995), pp. 1321-1326
[92.]
R.C. Colgrove, J. Pitt, P. Hua Chung, S.L. Welles, A.J. Japour.
Selective vertical transmission of HIV-1 antiretroviral resistance mutations.
AIDS, 12 (1998), pp. 2281-2288
[93.]
P.S. Eastman, D.E. Shapiro, R.W. Coombs, L.M. Frenkel, G.D. McSherry, P. Britto, et al.
Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076.
J Infect Dis, 177 (1998), pp. 557-564
[94.]
S.L. Welles, J. Pitt, R. Colgrove, K. McIntosh, P.H. Chung, A. Colson, et al.
HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.
AIDS, 14 (2000), pp. 263-271
[95.]
G. Bauer, J. Pitt, R. Colgrove.
and Welles S for the WITS Study Team.
Phenotipic zidovudine resistance and perinatal HIV-1 transmission, pp. 711
[96.]
R. Dickover, E. Garratty, S. Plaeger, Y. Briyson.
Perinatal Transmission of Major, Minor and Multiple HIV-1 Strains in Utero and Intrapartum.
pp. 181
[97.]
B. Masquelier, M. Burgard, A. Doussin, F. Simon, J. Cottalorda, J. Izopet, et al.
Zidovudine Genotypic resistance in HIV-1 Infected Newborn in the French HIV-1 Perinatal Cohort Study.
pp. 268
[98.]
J. Pitt, R. Colgrove, B. Thompson, A. Japour, S. Welles.
Association of Maternal ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance with Rapid Disease Progression among Infants in the WITS.
pp. 709
[99.]
A. Bardeguez, L.M. Mofenson, M. Fowler, et al.
Lack of clinical or immunological disease progression with transient use of zidovudine (ZDV) to reduce perinatal HIV transmission in PCATG 076.
pp. 12233
[100.]
J.B. Jackson, G. Becker-Pergola, L. Guay, P.h. Musoke, M. Mracna, M.G. Fowler, et al.
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
AIDS, 12 (2000), pp. F111-115
[101.]
J. Sullivan, c. Cunningham, A. Dorenbaum, L. Mofenson, M. Culnane, R. Gelber, et al.
Genotypic resistance analysis in women participating in PPACTG 316, with HIV-1 RNA>=10.000 copies/mL.
Programme Supplement, pp. 14
[102.]
C.K. Cunningham, P. Britto, R. Gelber, A. Dorenbaum, L. Mofenson, M. Culnane, et al.
for the PPACTG 315 Team.
Genotypic resistance analysis in women participating in PPACTG 316, with HIV-1 RNA>400 copies/ml, pp. 712
[103.]
The European Collaborative Study. Caesarean section and risk of vertical transmission of HIV-1 infection.
Lancet, 343 (1994), pp. 1464-1467
[104.]
Kind C for the Paediatric AIDS Group of Switzerland. Mother-to-.child transmission of human immunodeficiency virus type 1: influence of parity and mode of delivery.
Eur J Pediatr, 154 (1995), pp. 542-545
[105.]
P.A. Tovo, M. de Martino, C. Gabiano, L. Galli, N. Cappello, E. Ruga, et al.
Mode of delivery and gestational age influence perinatal HIV-1 transmission.
J Acquir Immune Def Syndr Hum Retrovirol, 11 (1996), pp. 88-94
[106.]
A. Maguire, E. Sánchez, C. Fortuny, J. Casabona.
Potential risk factors for vertical HIV-1 transmission in Catalonia, Spain: the protective role of cesarean section. The Working Group on HIV-1 vertical transmission in Catalonia.
AIDS, 11 (1997), pp. 1851-1857
[107.]
P.A. Thomas, J. Weedon, K. Krasinski, E. Abrams, N. Shaffer, P. Matheron, et al.
Maternal predictors of perinatal human immunodeficiency virus transmission.
Pediatr Infect Dis J, 13 (1994), pp. 489-495
[108.]
D.T. Dunn, M.L. Newell, M.J. Mayaux, C. Kind, C. Hutto, J.J. Goedert, W. Andiman.
Mode of delivery and vertical transmission of HIV-1: a review of prospective studies.
J Acquir Immune Defic Syndr Hum Retrovirol, 7 (1994), pp. 1064-1066
[109.]
L. Mandelbrot, M.J. Mayaux, A. Bongain, A. Berrebi, Y. Moudoub-Jeanpetit, J.L. Benifla, et al.
Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts.
Am J Obstet Gynecol, 175 (1996), pp. 661-667
[110.]
R.J. Simonds, R. Steketee, S. Nesheim, P. Matheson, P. Palumbo, L. Alger, et al.
Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. Perinatal AIDS Collaborative Transmission Studies.
AIDS, 12 (1998), pp. 301-308
[111.]
The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1. A Meta-analysys of 15 Prospective Cohort Studies.
N Engl J Med, 340 (1999), pp. 977-987
[112.]
J.S.A. Stringer, D.J. Rouse, R.L. Goldenberg.
Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission. The case for restraint.
JAMA, 284 (1999), pp. 1946-1949
[113.]
The European Mode of Delivery Collaboration. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial.
Lancet, 353 (1999), pp. 1035-1039
[114.]
A.E. Semprini, C. Castagna, M. Ravizza, S. Fiore, V. Savasi, M.L. Muggiasca, et al.
The incidence of complications after caesarean section in 156 HIVpositive women.
AIDS, 9 (1995), pp. 913-917
[115.]
J.S. Read, R. Tuomala, E. Kpamegan, C. Zorrilla, S. Landesman, G. Brown, et al.
Mode of delivery and postpartum morbidity among HIV-infected women: The Women and Infants Transmission Study (WITS.
J Acquir Inmune Defic Syndr, 26 (2001), pp. 236-245
[116.]
H. Watts, L. Mofenson, J. Whitehouse, J. Read, R. Stiehm, J. Lambert, et al.
Complications according to mode of delivery among HIV-positive women with CD4 counts <500.
pp. 684
[117.]
T.A. Gruber, D. Reindell, R. Kästner, R. Lutz-Friedrich, B.H. Belohradsky, O. Dathe.
Complications after caesarean section in HIV-1 infected women not taking antiretroviral treatment.
Lancet, 354 (1999), pp. 1612-1613
[118.]
J.M. Peña.
Transmisión vertical del VIH-1.¿Hasta dónde se puede reducir?.
Med Clin (Barc, 114 (2000), pp. 297-298
[119.]
V.V. Santos, F.I. Bastos, K. Nielsen, M. Morgado, J.H. Pilotto, E. Joao, et al.
A prospective study of the feasibility of rapid HIV testing in pregnant women during the peripartum period in Rio de Janeiro, Brazil.
pp. 695
[120.]
S.A. Nogueira, J.S. Lambert, A.L. Alburquerque, R.R. Bornia, M. Diaz, N. Constantine.
Assessing rapid HIV testing in labor and delivery: A pilot study from Rio de Janeiro.
pp. 696
[121.]
J. Read.
Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective studies.
pp. 659
[122.]
American Academy of Pediatrics. HIV infection and AIDS.
2000 Red Book: Report of the Committee on Infectious Diseases (25ª ed.), pp. 325-350
[123.]
K. Luzuriaga, Y. Bryson, P. Krogstad, J. Robinson, B. Stechenberg, M. Lamson, et al.
Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection.
N Engl J Med, 336 (1997), pp. 1343-1349
[124.]
K. Luzuriaga, M. Mc Manus, M. Catalina, S. Mayack, M. Sharkey, M. Stevenson, J.L. Sullivan.
Early therapy of vertical HIV-1 infection: evidence for cessation of viral replication and absence of virus-specific immunity.
[125.]
Vigilancia epidemiológica del sida en España: Informe trimestral nº 4, 1999. Secretaría del Plan Nacional sobre el Sida. Ministerio de Sanidad y Consumo
[126.]
M.R. Araneta, I. Mascola, A. Eller, I. O’neil, M.M. Ginsberg, M. Bursaw, et al.
HIV transmission through donor artificial insemination.
JAMA, 273 (1995), pp. 854-858
[127.]
B. Baccetti, A. Benedetto, A.G. Burrini, G. Collodel, E.C. Ceccarinil, N. Crisa, et al.
HIV particles in spermatozoa of patients with AIDS and their transfer into the oocytes.
J Cell Biol, 127 (1994), pp. 903-914
[128.]
T.C. Quinn, M.J. Wawer, N. Sewankambo, D. Serwadda, C. Li, F. Wabwire-Mangen, et al.
Viral load and heterosexual transmission of human immunodeficiency virus type 1.
N Engl J Med, 342 (2000), pp. 921-929
[129.]
P. Gupta, J. Mellors, L. Kingsley, S. Riddler, M.K. Shing, S. Schreiber, et al.
High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.
J Virol, 71 (1997), pp. 5271-5275
[130.]
P.L. Vernazza, B.L. Gilliam, J. Dyer, S.A. Fiscus, J.J. Eron, A.C. Frank, M.S. Cohen.
Quantification of HIV in semen: correlation with antiviral treatment and immune status.
AIDS, 11 (1997), pp. 987-993
[131.]
A.T. Haase, T.W. Schacker.
Potential for the transmission of HIV-1 despite highly active antiretroviral therapy.
N Engl J Med, 339 (1998), pp. 1846-1848
[132.]
H. Zhang, G. Dornadula, M. Beumont, L. Livornese, B. Van Uitert, K. Henning, R.J. Pomerantz.
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
N Engl J Med, 339 (1998), pp. 1803-1809
[133.]
R.W. Coombs, C.E. Speck, J.P. Hughes, W. Lee, R. Sampoleo, S.O. Ross, et al.
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen ans HIV-1 levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood.
J Infect Dis, 177 (1998), pp. 320-330
[134.]
R.C. Eyre, G. Zheng, A.A. Kiessling.
Multiple drug resistance mutations in human immunodeficiency virus in semen but not blood of a man on antiretroviral therapy.
Urology (Online, 55 (2000), pp. 5
[135.]
L.U. Kim, M.R. Johnson, S. Barton, M.R. Nelson, G. Sontag, J.R. Smith, et al.
Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children.
AIDS, 13 (1999), pp. 645-651
[136.]
A. Semprini, P. Levis-Setti, M. Bozzo, M. Ravizza, A. Tagliorelli, P. Sulpizio, et al.
Insemination of HIV-negative women with processed semen of HIVpositive partners.
Lancet, 340 (1992), pp. 1317-1319
[137.]
A. Semprini, S. Fiore, G. Pardi.
Reproductive counselling of HIV-discordant couples.
Lancet, 349 (1997), pp. 1401-1402
[138.]
S. Marina, F. Marina, R. Alcolea, J. Nadal, R. Expósito, J. Huguet, et al.
Human immunodeficiency virus type-1 serodiscordant couples can bear healthy children after undergoing intrauterine insemination.
Fertil Steril, 70 (1998), pp. 35-39
[139.]
A. Veiga, O. Coll, R. Tur, et al.
Assisted reproductive technologies and HIV-1 serodiscordant couples.
Prenat Neonat Med, 4 (1999), pp. 357-361
[140.]
S. Marina, F. Marina, R. Alcolea, J. Nadal, R. Expósito, J. Huguet.
Pregnancy following intracytoplasmic sperm injection from an HIV-1 seropositve man.
Hum Reprod, 13 (1998), pp. 3247-3249
[141.]
Veiga A, Coll O, Tur R, Busquets A, BarriI PN. Assisted reproductive technologies and HIV-1 serodiscordant couples. Eur J Obst Gynecol (en prensa)aa
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos